Navigation Links
InterMune Receives European Union Approval for Esbriet® (pirfenidone)
Date:3/3/2011

BRISBANE, Calif., March 3, 2011 /PRNewswire/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that the European Commission (EC) has granted marketing authorization for Esbriet® (pirfenidone).  Esbriet is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  The approval authorizes marketing of Esbriet in all 27 EU member states, and marks a significant turning point for the treatment of IPF patients in Europe.  More than 100,000 patients suffer from IPF in the 10 nations that comprise the most-populated European countries; approximately 87,000 patients in the five largest countries of Germany, France, Spain, Italy and the United Kingdom.  

"InterMune is proud to bring the first IPF medicine, Esbriet, to patients in Europe," said Dan Welch, Chairman, Chief Executive Officer and President of InterMune.  "We are very pleased with our approved label for Esbriet and believe it will effectively support the access, pricing, reimbursement and marketing of Esbriet in Europe.  The approval of Esbriet not only marks an historic moment in the treatment of IPF patients, but also an exciting new chapter for our company as we now transition to become an international commercial organization.  Our seasoned leadership team in the EU is working very diligently to make Esbriet available to European patients as soon as possible, beginning with Germany in September of this year."  

Based on anticipated EU country reimbursement timelines, InterMune currently plans to launch Esbriet in the so-called "Top 5" EU countries as follows: Germany in September of 2011; France, Spain and Italy in the first half of 2012 and in the United Kingdom in mid-2012.  InterMune also plans to launch Esbriet in all or substantially all of the 10 most important pharmac
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. InterMune Reports Fourth Quarter and Full Year 2010 Financial Results and Business Highlights
2. InterMune to Present at J.P. Morgan Healthcare Conference
3. InterMune Reports Third Quarter 2010 Financial Results
4. InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
5. InterMune to Release Second Quarter Financial Results on July 27
6. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
7. FDA Advisory Committee Recommends Approval of InterMunes Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis
8. InterMune Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Pirfenidone
9. InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
10. InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010
11. InterMune to Present at Deutsche Bank Biotech Confab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... and TARRYTOWN, N.Y. , May 21, ... and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that ... online the positive Phase 2a study results of dupilumab ... an investigational monoclonal antibody targeting the alpha subunit of ... of both IL-4 and IL-13, drivers of Th2 (Type ...
(Date:5/21/2013)... 2013  Healthcare organizations expanding into emerging markets like ... , India and ... shortcuts.  This is proving particularly challenging, considering the current ... change the dialogue around BRIC, as it is now ... building regional partnerships to build a sustainable business. ...
(Date:5/21/2013)... 2013 U.S. spending on specialty prescription drugs ... as cancer, multiple sclerosis and rheumatoid arthritis — is ... 2015, according to a forecast released today by Express ... ) "As we see what,s on ... to act so they can continue to offer an ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets 2Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets 3Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets 4U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 2U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 3U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 4U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 5
... June 2, 2011 As global food insecurity reaches ... how one company can impact this growing crisis. Today, ... 100,000 families globally through a partnership with Heifer International. ... and Company, a leading global pharmaceutical corporation, is also ...
... Siemens Healthcare (NYSE: SI) will ... workflow management solutions at the Society for Imaging Informatics ... 2011, (booth 825) in the Gaylord National Resort and ... facing increased pressure to provide faster, more accurate diagnoses ...
Cached Medicine Technology:Elanco Announces Commitment to Fight World Hunger 2Elanco Announces Commitment to Fight World Hunger 3At SIIM 2011 Siemens Showcases Imaging IT Solutions for Driving Greater Value in Radiology and Other Specialties 2At SIIM 2011 Siemens Showcases Imaging IT Solutions for Driving Greater Value in Radiology and Other Specialties 3At SIIM 2011 Siemens Showcases Imaging IT Solutions for Driving Greater Value in Radiology and Other Specialties 4
(Date:5/21/2013)... May 21, 2013 Access MediQuip, ... implant management company, announced today that it has expanded ... of the nation's largest health benefits companies, with more ... and approximately 66 million individuals served through its subsidiaries. ... national surgical implant management program agreement back in 2008. ...
(Date:5/21/2013)... Beginning May 21st, 2013, DTP Sales & Service ... newest in digital recording technology, to the hands of ... anyone looking to get the most from technology professional ... is expected to have revolutionary options and impeccable design. ... features and highlights: ,      ...
(Date:5/21/2013)... May 21, 2013 Tools4ever, the market ... made its Self Service Reset Password Management (SSRPM) suitable ... can now use the service on mobile systems i.e.; ... users can easily reset their Windows passwords anywhere, anytime. ... questions correctly, the user may then reset his or ...
(Date:5/21/2013)... Alan Mozes HealthDay Reporter , , MONDAY, ... used by millions of people with chronic obstructive ... cardiovascular complications among older patients, a new large ... patients over age 65 who are prescribed long-acting ... beta-agonists (such as Serevent). Both medications are commonly ...
(Date:5/21/2013)... The surgical management of non-small cell lung cancer (NSCLC) ... of the patient, according to a new study., "In ... Stage II NSCLC is surgery," said researcher Jayanth Adusumalli, ... Nebraska. "In our study of more than 1,200,000 patients ... 2000 and 2010, we found statistically significant racial disparities ...
Breaking Medicine News(10 mins):Health News:Access MediQuip and WellPoint Renew and Expand National Contract for Implantable Medical Devices 2Health News:Access MediQuip and WellPoint Renew and Expand National Contract for Implantable Medical Devices 3Health News:DTP Sales & Service Announces Upcoming Availability Of Philips Pocket Memo 8000 Series 2Health News:Tools4ever’s password reset software ready for BYOD 2Health News:Certain COPD Meds Might Raise Heart Risks, Study Says 2Health News:Certain COPD Meds Might Raise Heart Risks, Study Says 3
... Senior Vice President Brent Rickles Explains How to Protect ... ... Scottsdale, Ariz. (PRWEB) September 10, 2008 ... security management, launches a customer http://www.lumension.com/request_form.jsp?id=142756&rpLeadSourceId=1 [podcast ...
... recently launched to the online scene to cater to people who ... moments. Pampering one,s self is a most deserved treat for ... ... 10, 2008 -- Premised upon totally hassle-free virtual shopping, www.personalcaredeals.com ...
... Medicare; identifies best options and guides people through the process ... ... Ill. (Vocus) September 10, 2008 -- http://www.allsup.com/ [Allsup] ... individuals with disabilities with the introduction of http://www.allsup.com/Medicare-Advisor.aspx ...
... DSM Pharmaceutical Products,(DPP) announced today the ... of,record for marketing services. This relationship, in ... DSM business group and its three business,units: ... Pharmaceuticals, Inc., DSM Pharmaceutical Products offers ...
... private equity investors have increasingly targeted nursing homes ... anecdotal evidence that these deals led to worsened ... under increased federal scrutiny. , But according ... premature. Private equity purchases of nursing homesmany of ...
... C14-UBT are the most commonly used non-invasive tests of ... depend also on the prevalence of H. pylori ... tests depend also on the prevalence of H. pylori ... higher sensitivity and lower specificity. There are reports suggesting that ...
Cached Medicine News:Health News:Lumension Security Launches Podcast On Application Whitelisting: Keep The Bad Guys Out - Let The Good Guys In 2Health News:Lumension Security Launches Podcast On Application Whitelisting: Keep The Bad Guys Out - Let The Good Guys In 3Health News:Lumension Security Launches Podcast On Application Whitelisting: Keep The Bad Guys Out - Let The Good Guys In 4Health News:A One-Stop Online Shop For Personal Pampering Needs 2Health News:A One-Stop Online Shop For Personal Pampering Needs 3Health News:Allsup's New Medicare Advisor Program Helps People with Disabilities Make Sound Healthcare Coverage Decisions 2Health News:Allsup's New Medicare Advisor Program Helps People with Disabilities Make Sound Healthcare Coverage Decisions 3Health News:Allsup's New Medicare Advisor Program Helps People with Disabilities Make Sound Healthcare Coverage Decisions 4Health News:Allsup's New Medicare Advisor Program Helps People with Disabilities Make Sound Healthcare Coverage Decisions 5Health News:DSM Pharmaceutical Products Announces the Appointment of That's Nice LLC as Agency of Record for Marketing 2Health News:DSM Pharmaceutical Products Announces the Appointment of That's Nice LLC as Agency of Record for Marketing 3Health News:Private equity companies purchase nursing homes, but care does not suffer 2Health News:Private equity companies purchase nursing homes, but care does not suffer 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: